skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Datamonitor Healthcare attended the 2013 European Cancer Congress (ECCO 17-ESMO 38-ESTRO 32) which took place between 27 September and 1 October in Amsterdam, Netherlands.

Highlights from this whitepaper include:

Results from Kadcyla Phase III Trial, TH3RESA, and the impact this will have on the breast cancer market

Insight into BioMarin’s PARP inhibitor BMN-763 and it’s effectiveness for BRCA mutation-positive metastatic breast cancer patients

Find out the likelihood of trebananib/paclitaxel regimen being approved


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: